Eric C. Lacasse

Ottawa, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

TWEAK-induced alternative NF-κB signaling regulates Cxcl10 and Mymx to promote myoblast-to-myotube fusion and muscle regeneration.

TWEAK-induced alternative NF-κB signaling regulates Cxcl10 and Mymx to promote myoblast-to-myotube fusion and muscle regeneration.

Journal: Communications biology

Published: August 19, 2025

Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade.

Enhanced glioblastoma immunotherapy via SMAC mimetic dose escalation and TGFβ blockade.

Journal: Neuro-oncology advances

Published: June 16, 2025

Cell death in glioblastoma and the central nervous system.

Cell death in glioblastoma and the central nervous system.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: October 20, 2024

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study.

Journal: Therapeutic advances in medical oncology

Published: October 08, 2024

Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds.

Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds.

Journal: Cell death & disease

Published: April 01, 2024

Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.

Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.

Journal: Nature cardiovascular research

Published: January 05, 2024

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.

Journal: Frontiers in immunology

Published: March 04, 2023

Selective JAK1 inhibitors for the treatment of inflammatory bowel disease.

Selective JAK1 inhibitors for the treatment of inflammatory bowel disease.

Journal: Pharmacology & therapeutics

Published: December 15, 2022

IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn's disease.

IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn's disease.

Journal: Clinical and experimental immunology

Published: November 10, 2022

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?

Journal: Cell death & disease

Published: April 14, 2020

SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases.

SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases.

Journal: Science signaling

Published: February 20, 2020

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells.

Sp3-cificity of TNF-α expression promotes the Smac mimetic-mediated killing of cancer cells.

Journal: Molecular & cellular oncology

Published: March 21, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026